Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study

Rajagopalan, Harith, Cherrington, Alan D., Thompson, Christopher C., Kaplan, Lee M., Rubino, Francesco, Mingrone, Geltrude, Becerra, Pablo, Rodriguez, Patricia, Vignolo, Paulina, Caplan, Jay, Rodriguez, Leonardo, Galvao Neto, Manoel P. · 2016 · Diabetes Care

Abstract

OBJECTIVE: To assess procedural safety and glycemic indices at 6 months in a first-in-human study of duodenal mucosal resurfacing (DMR), a novel, minimally invasive, upper endoscopic procedure involving hydrothermal ablation of the duodenal mucosa, in patients with type 2 diabetes and HbA1c ≥7.5% (58 mmol/mol) on one or more oral antidiabetic agents. RESEARCH DESIGN AND METHODS: Using novel balloon catheters, DMR was conducted on varying lengths of duodenum in anesthetized patients at a single medical center. RESULTS: A total of 39 patients with type 2 diabetes (screening HbA1c 9.5% [80 mmol/mol]; BMI 31 kg/m2) were treated and included in the interim efficacy analysis: 28 had a long duodenal segment ablated (LS; ∼9.3 cm treated) and 11 had a short segment ablated (SS; ∼3.4 cm treated). Overall, DMR was well tolerated with minimal gastrointestinal symptoms postprocedure. Three patients experienced duodenal stenosis treated successfully by balloon dilation. HbA1c was reduced by 1.2% at 6 months in the full cohort (P < 0.001). More potent glycemic effects were observed among the LS cohort, who experienced a 2.5% reduction in mean HbA1c at 3 months postprocedure vs. 1.2% in the SS group (P < 0.05) and a 1.4% reduction at 6 months vs. 0.7% in the SS group (P = 0.3). This occurred despite net medication reductions in the LS cohort between 0 and 6 months. Among LS patients with a screening HbA1c of 7.5–10% (58–86 mmol/mol) and on stable antidiabetic medications postprocedure, HbA1c was reduced by 1.8% at 6 months (P < 0.01). CONCLUSIONS: Single-procedure DMR elicits a clinically significant improvement in hyperglycemia in patients with type 2 diabetes in the short-term, with acceptable safety and tolerability. Long-term safety, efficacy, and durability and possible mechanisms of action require further investigation.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-0383

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 219

Metadata

Authors
Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P.
Affiliations
  • Fractyl (United States) (US)
  • Vanderbilt University Medical Center (US)
  • Brigham and Women's Hospital (US)
  • Massachusetts General Hospital (US)
  • King's College London (GB)
  • Catholic University of Rome, Rome, Italy
  • CCO Clinical Center for Diabetes, Obesity and Reflux, Santiago, Chile
  • Gastro Obeso Center, São Paulo, Brazil
Corresponding author
Rajagopalan, Harith
Venue
Diabetes Care
Published
2016-08-12
Volume
39
Issue
12
Pages
2254-2261
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2514895276
Cited by
216
References
35
Citations by year
2026: 9 · 2025: 21 · 2024: 17 · 2023: 14 · 2022: 17 · 2021: 25 · 2020: 34 · 2019: 24 · 2018: 20 · 2017: 32 · 2016: 2
FWCI
26.06
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
Fractyl Laboratories, Inc
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
duodenal mucosal resurfacing, type 2 diabetes, HbA1c reduction, glycemic control, balloon catheter, duodenal stenosis, antidiabetic medication reduction, procedural safety, first-in-human study
MeSH terms
Adult, Aged, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Duodenum, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Intestinal Mucosa, Male, Middle Aged, Pilot Projects, Endoscopy, Gastrointestinal, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. https://app.cochat.ai/papers/10.2337/dc16-0383
The paper
Rajagopalan, H., Cherrington, A. D., Thompson, C. C., Kaplan, L. M., Rubino, F., Mingrone, G., Becerra, P., Rodriguez, P., Vignolo, P., Caplan, J., Rodriguez, L., & Galvao Neto, M. P. (2016). Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care. https://doi.org/10.2337/dc16-0383

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.